Aardvark Therapeutics (NASDAQ: AARD) posts new January 2026 presentation

Rhea-AI Filing Summary

Aardvark Therapeutics, Inc. filed a current report to note that on January 12, 2026 it updated its corporate presentation. The presentation, dated January 2026, is intended for meetings with investors, analysts and other stakeholders and will also be posted on the company’s website.

The updated corporate presentation is furnished as Exhibit 99.1 and is incorporated by reference into the Other Events section. The company states the presentation is current as of January 12, 2026 and disclaims any obligation to update this material in the future.

0001774857false00017748572026-01-122026-01-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

Aardvark Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-42513	82-1606367
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4370 La Jolla Village Drive, Suite 1050
San Diego, California				92122
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 225-7696

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		AARD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 12, 2026, Aardvark Therapeutics, Inc. (the “Company”) updated its corporate presentation for use in meetings from time to time with investors, analysts and others, which corporate presentation will also be posted to the Company’s website. A copy of the corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01. The presentation is current as of January 12, 2026, and the Company disclaims any obligation to update this material in the future.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Corporate Presentation, dated January 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			AARDVARK THERAPEUTICS, INC.
Date:	January 12, 2026	By:	/s/ Tien-Li Lee, M.D.
			Tien-Li Lee, M.D. Chief Executive Officer

FAQ

What did Aardvark Therapeutics (AARD) disclose in this 8-K filing?

Aardvark Therapeutics reported that it updated its corporate presentation on January 12, 2026. The presentation is intended for use in meetings with investors, analysts and others and will also be posted on the company’s website.

When is the new Aardvark Therapeutics (AARD) corporate presentation dated?

The corporate presentation is dated January 2026 and is stated to be current as of January 12, 2026.

Where can investors find the updated Aardvark Therapeutics (AARD) presentation?

The updated corporate presentation is filed as Exhibit 99.1 to the report and will also be posted on Aardvark Therapeutics’ website.

Does Aardvark Therapeutics (AARD) plan to update the January 2026 presentation?

The company states that the presentation is current as of January 12, 2026 and disclaims any obligation to update this material in the future.

Which exhibit in the filing contains the Aardvark Therapeutics (AARD) corporate presentation?

The updated corporate presentation is included as Exhibit 99.1. The filing also references Exhibit 104 for the cover page interactive data file.

What section of the 8-K covers the new Aardvark Therapeutics (AARD) presentation?

The updated corporate presentation is discussed under Item 8.01 Other Events in the report.